Kieran Rea1,2, Fiona McGowan1,2, Louise Corcoran1,2, Michelle Roche3,2, David P Finn1,2. 1. Pharmacology and Therapeutics, School of Medicine, National University of Ireland Galway, Galway, Ireland. 2. Galway Neuroscience Centre and Centre for Pain Research, NCBES, National University of Ireland Galway, Galway, Ireland. 3. Physiology, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Abstract
BACKGROUND AND PURPOSE: The emotional processing and coordination of top-down responses to noxious and conditioned aversive stimuli involves the medial prefrontal cortex (mPFC). Evidence suggests that subregions of the mPFC [infralimbic (IfL), prelimbic (PrL) and anterior cingulate (ACC) cortices] differentially alter the expression of contextually induced fear and nociceptive behaviour. We investigated the role of the endocannabinoid system in the IfL, PrL and ACC in formalin-evoked nociceptive behaviour, fear-conditioned analgesia (FCA) and conditioned fear in the presence of nociceptive tone. EXPERIMENTAL APPROACH: FCA was modelled in male Lister-hooded rats by assessing formalin-evoked nociceptive behaviour in an arena previously paired with footshock. The effects of intra-mPFC administration of AM251 [cannabinoid type 1 (CB1 ) receptor antagonist/inverse agonist], URB597 [fatty acid amide hydrolase (FAAH) inhibitor] or URB597 + AM251 on FCA and freezing behaviour were assessed. KEY RESULTS: AM251 attenuated FCA when injected into the IfL or PrL and reduced contextually induced freezing behaviour when injected intra-IfL but not intra-PrL or intra-ACC. Intra-ACC administration of AM251 alone or in combination with URB597 had no effect on FCA or freezing. URB597 attenuated FCA and freezing behaviour when injected intra-IfL, prolonged the expression of FCA when injected intra-PrL and had no effect on these behaviours when injected intra-ACC. CONCLUSIONS AND IMPLICATIONS: These results suggest important and differing roles for FAAH substrates or CB1 receptors in the PrL, IfL and ACC in the expression of FCA and conditioned fear in the presence of nociceptive tone. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
BACKGROUND AND PURPOSE: The emotional processing and coordination of top-down responses to noxious and conditioned aversive stimuli involves the medial prefrontal cortex (mPFC). Evidence suggests that subregions of the mPFC [infralimbic (IfL), prelimbic (PrL) and anterior cingulate (ACC) cortices] differentially alter the expression of contextually induced fear and nociceptive behaviour. We investigated the role of the endocannabinoid system in the IfL, PrL and ACC in formalin-evoked nociceptive behaviour, fear-conditioned analgesia (FCA) and conditioned fear in the presence of nociceptive tone. EXPERIMENTAL APPROACH: FCA was modelled in male Lister-hooded rats by assessing formalin-evoked nociceptive behaviour in an arena previously paired with footshock. The effects of intra-mPFC administration of AM251 [cannabinoid type 1 (CB1 ) receptor antagonist/inverse agonist], URB597 [fatty acid amide hydrolase (FAAH) inhibitor] or URB597 + AM251 on FCA and freezing behaviour were assessed. KEY RESULTS: AM251 attenuated FCA when injected into the IfL or PrL and reduced contextually induced freezing behaviour when injected intra-IfL but not intra-PrL or intra-ACC. Intra-ACC administration of AM251 alone or in combination with URB597 had no effect on FCA or freezing. URB597 attenuated FCA and freezing behaviour when injected intra-IfL, prolonged the expression of FCA when injected intra-PrL and had no effect on these behaviours when injected intra-ACC. CONCLUSIONS AND IMPLICATIONS: These results suggest important and differing roles for FAAH substrates or CB1 receptors in the PrL, IfL and ACC in the expression of FCA and conditioned fear in the presence of nociceptive tone. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
Authors: Kieran Rea; Weredeselam M Olango; Bright N Okine; Manish K Madasu; Iseult C McGuire; Kathleen Coyle; Brendan Harhen; Michelle Roche; David P Finn Journal: Pain Date: 2013-09-25 Impact factor: 6.961
Authors: D P Finn; M D Jhaveri; S R G Beckett; A Madjd; D A Kendall; C A Marsden; V Chapman Journal: Neuroscience Date: 2006-01-19 Impact factor: 3.590
Authors: D P Finn; M D Jhaveri; S R G Beckett; C H Roe; D A Kendall; C A Marsden; V Chapman Journal: Neuropharmacology Date: 2003-10 Impact factor: 5.250
Authors: Carolina Y Reyes-Soto; Mariana Villaseca-Flores; Enid A Ovalle-Noguez; Jade Nava-Osorio; Sonia Galván-Arzate; Edgar Rangel-López; Marisol Maya-López; Socorro Retana-Márquez; Isaac Túnez; Alexey A Tinkov; Tao Ke; Michael Aschner; Abel Santamaría Journal: Neurotox Res Date: 2022-09-07 Impact factor: 3.978
Authors: Jessica C Gaspar; Bright N Okine; Alvaro Llorente-Berzal; Michelle Roche; David P Finn Journal: Molecules Date: 2020-02-24 Impact factor: 4.411
Authors: Karla Chavira-Ramos; Mario Orozco-Morales; Çimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González Journal: Neurotox Res Date: 2020-11-03 Impact factor: 3.911